Clinics and Departments

Laboratory Services

Lab Dept:

Serology

Test Name:

IBD SEROLOGY

General Information

Lab Order Codes:

IBDS

Synonyms:

Crohn’s Disease; Neutrophil specific Ab; Imflammatory Bowel Disease serology

CPT Codes:

83520 x2 - Immunoassay, analyte, quantitative; not otherwise specified

86255 – Fluorescent noninfectious agent Ab; screen, each Ab

Test Includes:

ASCA IgA, ASCA IgG, NSA (Neutrophil specific antibodies)

Logistics

Test Indications:

Useful as an adjunct in the diagnosis of UC and CD in patients suspected of having IBD

Lab Testing Sections:

Serology - Sendouts

Referred to:

Mayo Medical Laboratories (Test#: 81443)

Phone Numbers:

Minneapolis:

Saint Paul:

 

612-813-6280

651-220-6550

Test Availability:

Daily, 24 hours

Turnaround Time:

3 - 5 days

Special Instructions:

N/A

Specimen

Specimen Type:

Blood

Container:

Red top or serum gel tube(s)

Draw Volume:

Minimum: 1.5 mL blood

Processed Volume:

Minimum: 0.5 mL serum

Collection:

Routine venipuncture

Special Processing:

Lab Staff: Centrifuge specimen, remove serum aliquot into a screw-capped round bottom plastic vial. Store and ship at refrigerated temperatures. Forward promptly.

Patient Preparation:

None

Sample Rejection:

Mislabeled or unlabeled specimens

Interpretive

Reference Range:

Assay

Reference Range

ASCA IgA

Negative: 0.0 – 20.0 U

Equivocal: 20.1 – 24.9 U

Weakly positive: 25.0 – 34.9 U

Positive: > or =35.0 U

ASCA IgG

Negative: 0.0 – 20.0 U

Equivocal: 20.1 – 24.9 U

Weakly positive: 25.0 – 34.9 U

Positive: > or =35.0 U

NSA

Negative (not detectable)

Critical Values:

N/A

Limitations:

Results from this test should not be exclusively relied upon to establish the diagnosis of UC or CD or to distinguish between these 2 diseases. Some patients with CD have detectable NSA, and some patients with UC have elevated levels of IgA and/or IgG ASCA.

Approximately 1/3 of patients have low titered anti-nuclear antibodies (ANA), which make it impossible to distinguish the presence or absence of NSA. These results are reported as indeterminate.

Not useful to determine the extent of disease in patients with IBD or determine the response to disease-specific therapy including surgical resection of diseased intestine.

Methodology:

Enzyme-Linked Immunosorbent Assay (ELISA)

Indirect Immunofluorescent Assay (IFA)

References:

Mayo Medical Laboratories December 2009



  Lab Test Directory
    Chemistry
    Coagulation
    Flow/Immunology
    Hematology
    Microbiology/ Virology
    Other Fluids
    Pathology
    Serology
    Transfusion Services
    Urine/Stool

  Search Lab Test Directory
    List All Documents

  Lab Staff

  E-mail Lab Services